DuPont Decomposition

Why does AMBUJACEM earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

8.0% = 11.8% × 0.45 × 1.51

Latest: FY2026

Profitability

Net Margin

11.8%

7.8% →11.8%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.45x

0.75x →0.45x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.51x

1.63x →1.51x

Assets funded by equity vs debt

Trend Analysis

ROE declined by 1.6 pp over 4 years. Driven by net margin improving (7.8% → 11.8%), asset turnover declining (0.75x → 0.45x).

Historical Decomposition

Last 4 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20230Cr0Cr7.8%0.751.639.5%
FY20240Cr0Cr11.0%0.501.578.6%
FY20250Cr0Cr12.8%0.411.518.0%
FY20260Cr0Cr11.8%0.451.518.0%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for AMBUJACEM

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

AMBUJACEM DuPont Analysis — ROE 8.0% | YieldIQ